Abstract 35P
Background
Current immune research on soft tissue sarcomas (STS) primarily focuses on analyzing the tumor microenvironment and adjacent lymph nodes. However, alternative methods are necessary to monitor immune responses in non-surgical patients due to limited opportunities to study tumor-infiltrating lymphocytes. This study aimed to assess the peripheral immune profile of STS patients and its impact on patient survival.
Methods
Blood samples were collected from 55 STS patients and age-matched healthy individuals. Flow cytometry and qRT-PCR were conducted on whole blood, to proceed with deep immunophenotyping and gene expression quantification, respectively. Proteomic analysis was also performed on plasma samples by xMAP technology. Unsupervised clustering analysis was used to classify patients based on their immunotype.
Results
Significant differences were found between STS patients and healthy individuals. STS patients showed lymphopenia, particularly affecting B and CD4 T cells, with an expansion of myeloid cells such as granulocytes and monocytic-derived suppressor cells (M-MDSC). Gene expression analysis revealed decreased levels of activatory and cytotoxic-related factors, along with increased expression of ARG1, which may inhibit anti-tumoral activity. A tendency for increased levels of IL-10 and soluble checkpoint inhibitors VISTA and TIMD-4 were also observed in plasma samples. Furthermore, patients were classified into three distinct immunotypes: \"immune-high,\" \"immune-intermediate,\" and \"immune-low.\" These immunotypes correlated significantly with time after collection (TAC), which refers to the time from sample collection to the end of the study or occurrence of a death event. \"Immune-high\" patients had elevated levels of immune-related factors associated with cytotoxic/effector activity and longer TAC, while \"immune-low\" patients had increased levels of immune-related factors associated with inflammation and inhibition, and shorter TAC.
Conclusions
The correlation between immunotypes and survival times emphasizes the importance of studying peripheral blood samples in STS. Evaluating the peripheral immune response can be a valuable tool for monitoring and predicting outcomes in STS patients.
Legal entity responsible for the study
The authors.
Funding
FCT - Portuguese Foundation for Science and Technology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
36P - Expression of germinal center B cell- and Th17 cell-related transcripts are prognostic of soft-tissue sarcoma patient outcomes
Presenter: Giulia Petroni
Session: Poster Display
38P - Machine learning-based pathomics model to predict the infiltration of Treg and prognosis in IDH-wt GBM
Presenter: Shaoli Peng
Session: Poster Display
40P - The role of low avidity tumour-specific CD8+ T cells in immunotherapeutic response to anti-PD-1
Presenter: Doreen Lau
Session: Poster Display
41P - Contrasting drivers of response to immunotherapy across solid tumour types: results from analysis of >2500 cases
Presenter: Danwen Qian
Session: Poster Display
42P - TCCIA: A Comprehensive Resource for Exploring CircRNA in Cancer Immunotherapy
Presenter: Jian-Guo Zhou
Session: Poster Display
43P - Immune and tumor cells expression of VISTA in a panel of cancer indications: A strategy to inform selection of patients treated with anti-VISTA
Presenter: Pierre Launay
Session: Poster Display
44P - Exploratory Analysis of Peripheral Pharmacodynamic (PD) Biomarkers After Sitravatinib (Sitra) and Tislelizumab (TIS) in Advanced Solid Tumors: SAFFRON-103
Presenter: Yi-Long Wu
Session: Poster Display
45P - Protein biomarkers associated with organ-specific immune-related toxicity and response to management identified by proteome analysis of extracellular vesicles from plasma
Presenter: Anders Kverneland
Session: Poster Display
46P - Immunoprofiling of Peripheral Blood Cells as a Potential Predictor of Immune-Related Toxicity of PD-1 Inhibitors
Presenter: Jan Podhorec
Session: Poster Display